Journal

Why Multi-Dose Vials Create Tirzepatide Dosing Errors

Educational safety article; no personalized dosing

A packaging difference with clinical consequences

An approved GLP-1 arrives as a pen or a single-dose vial delivering a fixed amount. The dose is a device function; the patient cannot easily give themselves ten times the intended amount.

Many compounded products arrive as a multi-dose vial and a syringe. The patient draws each dose themselves, converting a dosing decision into a measurement task performed at home, often weekly, frequently by someone who has never used a syringe before.

Where the errors come from

The failure mode is unit confusion. Compounded products vary in concentration between pharmacies, so instructions may be given in milligrams, in millilitres, or in insulin-syringe "units" — and the relationship between those depends entirely on the concentration of the specific vial.

A patient told to draw "10 units" who applies a conversion from a different concentration can administer several times the intended dose. The FDA has documented reports of exactly this pattern, including cases requiring hospitalisation, and the agency has cited dosing errors from self-administration out of multidose vials as a specific concern in its enforcement posture toward compounded GLP-1s.

What to establish before your first injection

1. The concentration of your vial, in milligrams per millilitre. Not the dose — the concentration.
2. Your dose in millilitres, calculated for that concentration, written down.
3. Which syringe you are using. Insulin syringes are marked in units calibrated for insulin, not for whatever is in your vial.
4. Who to call if the instructions and the markings do not correspond. A chat widget is not an adequate answer for a dosing question.

If a provider cannot give you these in writing, that is worth knowing before you inject rather than after.

What this is not

It is not an argument that every compounded product is dangerous, and it is not a claim about any specific pharmacy. It is a structural observation: moving dose measurement from a manufacturing process to a patient's kitchen introduces a category of error that pens and single-dose vials do not have, and the reported harms follow from that.

Why the approved products do not have this problem

An approved GLP-1 arrives as a pen or single-dose vial delivering a fixed amount. The dose is engineered into the device. A patient cannot easily administer ten times the intended quantity because the device does not permit it.

Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL — one strength per presentation. The dose decision happens at the prescription, not at the kitchen table.

The conversion that goes wrong

Insulin syringes are marked in "units" calibrated for insulin at 100 units per mL. A compounded GLP-1 vial may be at any concentration the pharmacy chose. The relationship between a marking on the barrel and a milligram of drug therefore depends entirely on your specific vial.

A patient told to "draw 10 units" who applies a conversion learned from a different concentration — a forum post, a previous vial, a friend's instructions — can administer several times the intended dose. This is the pattern behind the reported hospitalisations, and it is a measurement error rather than a prescribing one.

What good practice looks like

A provider running this properly gives you the concentration in mg/mL, your dose in millilitres calculated for that concentration, a syringe matched to that calculation, and a named contact for dosing questions. Some provide a demonstration.

A provider that sends a vial, a syringe and a dose in milligrams has handed you an arithmetic problem with clinical consequences.

If you are already using a multi-dose vial

1. Write your dose in millilitres on the vial itself, alongside the concentration.
2. Photograph the instructions you were given, so you are not relying on memory at week nine.
3. Confirm the concentration every time a new vial arrives — compounders change formulations.
4. If the instructions and the syringe markings do not correspond, do not inject. Contact the prescriber.

Why this is a design problem rather than a blame problem

The patients making these errors are not careless. They are doing arithmetic under conditions no other part of their pharmacy experience requires: converting between units and volumes, weekly, from instructions written by someone who will not see them do it.

Approved products removed that task by engineering the dose into the device. Reintroducing it is a design decision made for cost reasons, and the resulting error rate is a property of the design.

What to ask before your first vial arrives

Whether the product is single-dose or multi-dose. If multi-dose, the concentration in mg/mL, your dose in millilitres, and which syringe to use — all in writing, before delivery rather than after.

A provider that treats those as reasonable questions is running a safe programme. One that treats them as unusual is telling you how much support you will get at week nine.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask